News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

ERYtech Pharma Announces Enrollment Of First Patient In Phase II Study Of ERY-ASP In Pancreatic Cancer


7/28/2014 10:30:46 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

LYON, France--(BUSINESS WIRE)--Regulatory News: ERYTECH Pharma (Paris:ERYP) (Euronext Paris: FR0011471135 - ERYP), the French biopharmaceutical company that develops innovative ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs, announces the enrollment of the first patient in its Phase II study with ERY-ASP in second line treatment of patients affected by pancreatic cancer.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES